8CC.F COCRYSTAL PHARMA NEW O.N.

Healthcare Biotechnology Frankfurt Exchange
0.9000 EUR
Close of Nov 11, 2026
0.6900 1.30
Market cap
EUR 17.3M
P/E
-
P/B
19.77x
ROE
-1,046.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 8CC.F undervalued?

Graham number

The Graham number of COCRYSTAL PHARMA NEW O.N. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

COCRYSTAL PHARMA NEW O.N. fundamental analysis

No fundamental analysis for COCRYSTAL PHARMA NEW O.N. yet.

COCRYSTAL PHARMA NEW O.N. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About COCRYSTAL PHARMA NEW O.N.

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections. The company develops CC-42344, a novel PB2 inhi…

Full company profile